- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
Lumera Corporation (NASDAQ: LMRA), a leader in the emerging field of nanotechnology, announced today the release of its newest podcast interviews with Dr. Sam Gambhir, professor of radiology and bioengineering, Director of the Molecular Imaging Program and head of the nuclear medicine division at Stanford University as well as an interview with Dr. Jonathan Wells, Principal Partner at AJIS LLC, a broadband wireless technology consultancy and recently Director of Product Management and International Regulatory Affairs for GigaBeam.
Dr. Sam Gambhir, who was featured in "The End of Medicine," a book documenting the revolutionary developments and the future of medicine, is an expert in next generation drug discovery and molecular imaging. Dr. Gambhir serves as a member of Lumera's board.
"We are working to convince the scientific community and public that the future for imaging lies in the ability to detect what's going on at the cellular and molecular level," said Dr. Gambhir in his podcast interview. "As we are working to develop tools that will let us image at the molecular level, the future of molecular imaging will result in medicine that is geared for a given individual. For example a patient will get a study that is based on their genetic make-up as opposed to one imaging study that is a one-size fits all."
Dr. Jonathan Wells is an expert in wireless communications, having published over 30 technical papers on the subject. He has brought numerous high frequency/ high capacity wireless products to market for three NASDAQ-listed companies, most recently at GigaBeam, a company engaged in the millimeter-wave wireless space. Dr. Wells has also been driving the commercialization and marketing strategy of Lumera's 10 Gbps millimeter-wave communications system.
"What is really different about Lumera is that, for the first time in the industry, the wireless system uses a photonic platform rather than an electronic platform and that has opened up a whole new host of options," said Dr. Wells in his podcast interview. "Also, Lumera announced that the product is ten times the data rate of anything else that is commercially available. We have seen wireless technologies that can do one gigabit per second, but Lumera's product running at ten gigabits per second is very significant."
"It's exciting to see Lumera's products assisting in breakthrough developments in science and technology," commented Lumera Chief Executive Officer Tom Mino. "Having top-level scientists and experts like Dr. Gambhir and Dr. Wells involved and benefiting from Lumera's products and services, really sheds light on the significance of our efforts and validates our focus for the future."
Earlier this year, Lumera announced the 2007 Lumera Experts Podcast Series featuring interviews with industry leaders who are familiar with Lumera's technology and are experts in nanotechnology, bio-arrays, drug discovery, electro-optics, and wireless technologies. Podcast interviews by Dr. Niro Ramachandran, a research associate at the Harvard Institute of Proteomics led by Dr. Josh LaBaer, Dr. Larry Dalton, a Professor of Chemistry and Electrical engineering at the University of Washington and Nobel Prize Nominee, Dr. Joseph Vallner, recently President and CEO of Capnia, and Tom Mino, CEO of Lumera, have all been previously featured as part of the series and are currently available to download on Lumera's website.
About Lumera Corporation
Lumera is a leader in the emerging field of nanotechnology. The company designs proprietary molecular structures and polymer compounds for the bioscience and communications/computing industries, both of which represent large market opportunities. The company also has developed proprietary processes for fabricating such devices. For more information, please visit http://www.lumera.com .
Certain statements contained in this release are forward-looking statements that involve a number of risks and uncertainties. Factors that could cause actual results to differ materially from those projected in the company's forward-looking statements include the following: market acceptance of our technologies and products; our ability to obtain financing; our financial and technical resources relative to those of our competitors; our ability to keep up with rapid technological change; government regulation of our technologies; our ability to enforce our intellectual property rights and protect our proprietary technologies; the ability to obtain additional contract awards and to develop partnership opportunities; the timing of commercial product launches; the ability to achieve key technical milestones in key products; and other risk factors identified from time to time in the company's SEC reports, including its Annual Report on Form 10-K, and its Quarterly Reports on Form 10-Q.
For more information, please click here
Dr. Helene Jaillet
The Summit Group Communications
Copyright © Business Wire 2007If you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
European Technology Platform for Nanomedicine and ENATRANS European Consortium Launch the 2nd edition of the Nanomedicine Award: The Award to be presented at BIO-Europe conference in Munich, November 2015 July 30th, 2015
Take a trip through the brain July 30th, 2015
Sol-gel capacitor dielectric offers record-high energy storage July 30th, 2015
Self-assembling, biomimetic membranes may aid water filtration August 1st, 2015
March 2016; 6th Int'l Conference on Nanostructures in Iran July 29th, 2015
Nanometrics Announces Upcoming Investor Events July 28th, 2015